ArticleClinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico2011
Tumour and serum MGMT promoter methylation and protein expression in glioblastoma patients.
Article in Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico, 2011. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 21 papers, 4 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
21 citing papers in PubMed, 4 syntheses or guidelines pooled it, 36 citations in OpenAlex.
- Blood-Based Biomarkers for Glioma in the Context of Gliomagenesis: A Systematic Review.Frontiers in oncology · 2021Pooled it
- Diagnostic value of circulating tumor DNA in molecular characterization of glioma: A meta-analysis.Medicine · 2020Pooled it
- The prognosis of MGMT promoter methylation in glioblastoma patients of different race: a meta-analysis.Neurochemical research · 2014Pooled it
- The prognostic value of MGMT promoter methylation in Glioblastoma multiforme: a meta-analysis.Familial cancer · 2013Pooled it
- Bevacizumab and temozolomide versus temozolomide alone as neoadjuvant treatment in unresected glioblastoma: the GENOM 009 randomized phase II trial.Journal of neuro-oncology · 2016Trial
- Prognosis ofSouth Asian journal of cancer · 2024Article
- Liquid biopsy: creating opportunities in brain space.British journal of cancer · 2023Review
- Recent advances in label-free optical, electrochemical, and electronic biosensors for glioma biomarkers.Biomicrofluidics · 2023Review
- Article
- Is the prognostic significance of O6-methylguanine- DNA methyltransferase promoter methylation equally important in glioblastomas of patients from different continents? A systematic review with meta-analysis.Cancer management and research · 2017Review
- A blood-based gene expression and signaling pathway analysis to differentiate between high and low grade gliomas.Oncology reports · 2017Article
- MGMT testing allows for personalised therapy in the temozolomide era.Tumour biology : the journal of the International Society for Oncodevelopmental Biology and Medicine · 2016Review
- Circulating glioma biomarkers.Neuro-oncology · 2015Review
- Glioma diagnostics and biomarkers: an ongoing challenge in the field of medicine and science.Expert review of molecular diagnostics · 2014Review
- MGMT promoter methylation in plasma of glioma patients receiving temozolomide.Journal of neuro-oncology · 2014Article
- Developing epigenetic diagnostics and therapeutics for brain disorders.Trends in molecular medicine · 2013Review
- Detection of MGMT, RASSF1A, p15INK4B, and p14ARF promoter methylation in circulating tumor-derived DNA of central nervous system cancer patients.Journal of applied genetics · 2013Article
- MGMT testing for glioma in clinical laboratories: discordance with methylation analyses prevents the implementation of routine immunohistochemistry.Journal of cancer research and clinical oncology · 2012Review
- DNA methylation profiling in the clinic: applications and challenges.Nature reviews. Genetics · 2012Review
- DNA methylation, histone modifications, and signal transduction pathways: a close relationship in malignant gliomas pathophysiology.Journal of signal transduction · 2012Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors at 3 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
introductionMethylation of the promoter of the MGMT gene and MGMT protein expression are recognized as predictive markers for response to alkylating chemotherapy in glioblastoma (GB). MATERIAL AND
methodsWe have assessed MGMT methylation with the methylation-specific polymerase chain reaction (MSP) in tumor samples from 70 GB patients and in serum samples from 37 of these patients. We have also assessed MGMT protein expression by immunohistochemical (IHC) analysis in tissue samples from 63 of these patients.
resultsWe found concordance between MGMT methylation status in tissue and serum (Cohen's Kappa = 0.586; p<0.0001). MSP for detection of non-methylated MGMT promoter in serum showed a sensitivity of 95.4% and a specificity of 60%, while the IHC methylation test showed a low specificity (8.9%). Patients whose MGMT promoter was methylated in tissue attained longer progression-free and overall survival. In the multivariate analysis, serum MGMT promoter methylation emerged as an independent factor for longer progression-free and overall survival.
conclusionSerum-based MGMT methylation analysis offers a promising alternative to tumor-based MGMT analysis in cases where tissue samples are unavailable.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.